Results 151 to 160 of about 60,513 (321)

Targeting the Ubiquitin–Proteasome System for Cancer

MedComm, Volume 6, Issue 10, October 2025.
This figure shows the mechanism of protein degradation by ubiquitin–proteasome system. The process begins with ubiquitin activation by the E1 enzyme, forming a thioester bond between E1's cysteine residue and ubiquitin's glycine carboxyl group, powered by ATP hydrolysis.
Zhaoyun Liu, Jiao Lai, Ziyu Ma, Jianhua Pan, Chun Yang, Rong Fu   +5 more
wiley   +1 more source

Ruxolitinib for Myelofibrosis [PDF]

New England Journal of Medicine, 2012
Steffen, Koschmieder, Adriane, Koppelle, Hans, Seifert   +2 more
openaire   +4 more sources

Effects of Splenectomy on Red-cell Production in Myelofibrosis [PDF]

, 1961
G. Wetherley‐Mein, N. F. Jones, Jack Pullan   +2 more
openalex   +1 more source

SNPs array karyotyping reveals a novel recurrent 20p13 amplification in primary myelofibrosis. [PDF]

, 2011
The molecular pathogenesis of primary mielofibrosis (PMF) is still largely unknown. Recently, single-nucleotide polymorphism arrays (SNP-A) allowed for genome-wide profiling of copy-number alterations and acquired uniparental disomy (aUPD) at high ...
Alesiani, F., De Nictolis, M., Donati, M., Emiliani, R., Finelli, C., Gazzola, A., Isidori, A., Laginestra, M., Mannu, C., Paolini, S., Piccaluga, P., Pileri, S., Righi, S., Rossi, M., Sagramoso Sacchetti, C., Sapienza, M., Tripodo, C., Valentini, M., Visani, G.   +18 more
core   +1 more source

Midostaurin in daily clinical practice of patients with advanced systemic mastocytosis

British Journal of Haematology, Volume 207, Issue 4, Page 1388-1396, October 2025.
Durable responses based on modified Valent, IWG‐MRT‐ECNM and PPR criteria were predominantly dose‐independent, making dose adjustments due to better tolerability more practicable in daily routine. Gradual tapering of midostaurin, prophylactic treatment with antihistamines and corticosteroids and timely initiation of subsequent therapy can prevent a ...
Johannes Lübke, Nicole Naumann, Timo Brand, Laurenz Steiner, Roland Repp, Georgia Metzgeroth, Alice Fabarius, Wolf‐Karsten Hofmann, Deepti H. Radia, Andreas Reiter, Juliana Schwaab   +10 more
wiley   +1 more source

Primary and Secondary Myelofibrosis: Its Relationship to "PNH-like Defect" [PDF]

, 1972
Chi-yen Kuo, G. Arthur Van Voolen, Alan N. Morrison   +2 more
openalex   +1 more source

Similarities and Differences Between Allogeneic Hematopoietic Cell and Organ Transplantation and What We Can Learn From Each Other to Guide Global Health Strategy

Clinical Transplantation, Volume 39, Issue 10, October 2025.
ABSTRACT Background Allogeneic hematopoietic cell transplantation (HCT) and solid organ transplantation (SOT) have evolved into successful, curative treatments for many severe congenital and acquired diseases. Both use medical products of human origin and should therefore have overarching regulatory frameworks.
Hildegard T. Greinix, Arthur Matas, Mickey B. C. Koh, Lydia Foeken, Nina Worel, Amanda Vinson, Hassan Ibrahim, Deirdre Sawinski, Adriana Seber, Maryam Valapour, Yoshiko Atsuta, Thilo Mengling, John Lake, Thomas Wekerle, Daniel Weisdorf   +14 more
wiley   +1 more source

Novel approaches in myelofibrosis

HemaSphere
AbstractMyelofibrosis (MF) is a clonal myeloid neoplasm characterized by bone marrow fibrosis, splenomegaly, and disease‐associated symptoms, as well as increased mortality, due to thrombosis, severe bleeding, infections, or progression to acute leukemia.
openaire   +4 more sources

Can somatic GATA2 mutation mimic germ line GATA2 mutation? [PDF]

, 2018
Somatic GATA2 mutation is associated with immunodeficiency and pulmonary alveolar proteinosis in a patient with myeloproliferative ...
Collin, M, Dickinson, R, Lipman, M, Lowe, D, Marafioti, T, Mitchell, C, Pocock, R, Sekhar, M   +7 more
core  

Final Results From a Large, Non‐Interventional, Phase 4 Study of Ruxolitinib for the Treatment of Myelofibrosis in Clinical Routine

European Journal of Haematology, Volume 115, Issue 4, Page 380-390, October 2025.
ABSTRACT JAKoMo was a long‐term, multicenter, non‐interventional study observing the efficacy, safety, and quality of life (QOL) effects of ruxolitinib (RUX), managed per clinical routine at investigator discretion, for treatment of 943 patients with myelofibrosis (MF) in 122 German centers.
Steffen Koschmieder, Susanne Isfort, Clemens Schulte, Lutz Jacobasch, Thomas Geer, Marcel Reiser, Michael Koenigsmann, Bernhard Heinrich, Jürgen Wehmeyer, Eyck von der Heyde, Hans Tesch, Benedikt Gröschl, Petra Bachhuber, Susanne Großer, Michael Koehler, Heike L. Pahl   +15 more
wiley   +1 more source